Verdict: Unsupported.

A 2024 publication proposed a cancer-treatment protocol involving ivermectin, mebendazole, and fenbendazole. However, the publication was not a randomized clinical trial and did not establish that the three drugs are effective cancer treatments.

What was actually published?

The publication cited in the claim was titled Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. It proposed a treatment approach that included ivermectin, mebendazole and fenbendazole among several other interventions.

The important distinction is that this was a proposed treatment protocol, not a controlled clinical study demonstrating improved tumor response, progression-free survival, overall survival or another validated cancer outcome.

Therefore, the existence of this publication cannot by itself establish that the drugs are effective cancer treatments.

Ivermectin

Ivermectin is an established antiparasitic medicine. Laboratory and animal studies have investigated possible anticancer mechanisms, and ivermectin continues to be investigated in oncology research.

However, evidence from laboratory experiments or animal models does not establish that a drug provides a clinically meaningful benefit to cancer patients. As of September 2026, ivermectin is not an approved cancer treatment and there is no robust clinical evidence establishing it as an effective treatment for human cancer.

Mebendazole

Mebendazole is also an established antiparasitic medicine and has attracted interest as a possible repurposed cancer drug.

Compared with fenbendazole, mebendazole has been studied in human cancer trials, so there is a larger clinical evidence base. Nevertheless, the available evidence remains insufficient to establish mebendazole as a general cancer treatment.

A 2026 observational study examining ivermectin together with mebendazole reported clinical benefits in some patients. The study was not randomized or controlled, and the journal subsequently issued an official Expression of Concern regarding questions about the study's data and methodology. Such findings therefore cannot be treated as proof that the combination is an effective cancer treatment.

Fenbendazole

Fenbendazole is primarily a veterinary antiparasitic drug and is not approved as a cancer treatment for humans.

Interest in fenbendazole has largely been driven by laboratory research, animal studies and individual case reports. These types of evidence can justify further investigation but cannot establish clinical efficacy.

A 2025 case series describing three cancer patients who used fenbendazole was subsequently retracted by Case Reports in Oncology in January 2026. The retraction notice cited concerns including an undeclared conflict of interest involving the first author and concluded that the issue could affect interpretation of the publication and its recommendations.

The retraction does not by itself establish that the reported patient outcomes were fabricated. It does mean that the publication should no longer be treated as valid peer-reviewed evidence supporting fenbendazole as a cancer treatment.

What the evidence establishes

• Ivermectin, mebendazole and fenbendazole have antiparasitic uses.
• Laboratory and preclinical studies have identified possible anticancer effects of some of these drugs.
• Mebendazole has been investigated in human cancer studies.
• Ivermectin continues to be investigated in oncology research.
• There is no established clinical evidence showing that fenbendazole is an effective human cancer treatment.
• There is no established clinical evidence showing that ivermectin is an effective general cancer treatment.
• The available evidence does not establish that the combination of ivermectin, mebendazole and fenbendazole is an effective cancer treatment.

Why the original claim is unsupported

A drug producing an effect against cancer cells in a laboratory is not equivalent to demonstrating that the drug treats cancer in humans. Individual patient reports and uncontrolled observational studies also cannot reliably determine whether a treatment caused an observed improvement.

For a claim that these drugs are effective cancer treatments to be established, substantially stronger clinical evidence would be required, including well-designed controlled trials demonstrating meaningful patient outcomes.

Conclusion

The 2024 publication cited by the claim proposed a treatment protocol involving ivermectin, mebendazole and fenbendazole, but it did not provide clinical trial evidence demonstrating that the drugs are effective cancer treatments.

Subsequent evidence has not established the claim. A fenbendazole case series was retracted in 2026, while a 2026 observational ivermectin-mebendazole study received an official Expression of Concern.

The current evidence supports further scientific investigation, but does not support presenting ivermectin, mebendazole and fenbendazole as proven cancer treatments or as substitutes for established cancer therapies.